IIB co-locators come from across the
life sciences spectrum and share a focus on accessing our resources
in order to move from idea to market. We provide state-of-the-art
technology and expertise, and flexible, cost-effective lease terms in
dedicated biotech lab space where IP can be fully protected.
Providing a new atom’s eye view in solving major farming challenges
Biologists often aim to retain the benefits of a natural process while eliminating any harm. Naturally occurring in most New Zealand pastoral grasses, the fungus Neotyphodium lolii confers to the grass valuable drought and insect resistance, but can also cause neurological problems, called ryegrass staggers, in livestock. Current strategies to address this use traditional selective grass breeding. But the AgResearch Structural Biology Laboratory, owned by New Zealand's largest Crown Research Institute and based at the Institute for Innovation in Biotechnology (IIB), is now seeking a more certain remedy based on the insights of structural biology.
Identifying the compounds in honey-based therapeutics that can deliver the most benefit
To get the best results from any health compound you need to know not only that it delivers benefits but also why. This approach has become standard with new therapeutics, but in also applying it to naturally-based treatments Comvita is now aiming to better explain their efficacy and thereby pursue new health benefits as well.
New therapeutics from unique technology
activating innate immune signaling
Along with discovery, biotech success often turns on prioritising precious resources. In mid-2010 Innate Therapeutics, which is developing a novel immune response technology, marked a milestone with a US$550,000 grant from the US National Multiple Sclerosis Society and EMD Serono to begin Phase 2 clinical trials for a potential treatment for the progressive form of Multiple Sclerosis (MS).